Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irx-4204. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 20/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 12/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 10/20 | 1.00 |
| ▸ | RARB | P10826 | 8/20 | 1.00 |
| ▸ | RARG | P13631 | 8/20 | 1.00 |
| ▸ | RARA | P10276 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irx-4204 SCHEMBL8330929 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL6230860 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL5860163 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL3437269 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL29357376 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL24767436 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244484 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244477 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244476 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244482 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368160-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING THYROID HORMONE NEUTRAL DOSES OF RXR AGONISTS | IO THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230129034-A1 | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS | Io Therapeutics, Inc. | 2023-04-27 | — | — | US | disclosed |
| EP-3426302-B1 | TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | IO THERAPEUTICS INC (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2017155577-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Io Therapeutics, Inc. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155578-A1 | TREATMENT OF MUSCULAR DISORDERS WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Io Therapeutics, Inc. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017075610-A1 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING THYROID HORMONE NEUTRAL DOSES OF RXR AGONISTS | Io Therapeutics, Inc. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129034-A1 | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS | RXRA, RXRB, RXRG | RXRA 1/4885RXRG 3/4885RXRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.